de Oliveira Claudia P M S, Simplicio Fernanda I, de Lima Vicencia M R, Yuahasi Katia, Lopasso Fabio P, Alves Venancio A F, Abdalla Dulcineia S P, Carrilho Flair J, Laurindo Francisco R M, de Oliveira Marcelo G
Instituto de Quimica, UNICAMP, CP 6154, CEP 13083-970, Campinas, São Paulo, Brazil.
World J Gastroenterol. 2006 Mar 28;12(12):1905-11. doi: 10.3748/wjg.v12.i12.1905.
To evaluate the potential of S-nitroso-N-acetylcysteine (SNAC) in inhibition of lipid peroxidation and the effect of oral SNAC administration in the prevention of nonalcoholic fatty liver disease (NAFLD) in an animal model.
NAFLD was induced in Wistar male rats by choline-deficient diet for 4 wk. SNAC-treated animals (n=6) (1.4 mg/kg per day of SNAC, orally) were compared to 2 control groups: one (n=6) received PBS solution and the other (n=6) received NAC solution (7 mg/kg per day). Histological variables were semiquantitated with respect to macro and microvacuolar fat changes, its zonal distribution, foci of necrosis, portal and perivenular fibrosis, and inflammatory infiltrate with zonal distribution. LOOHs from samples of liver homogenates were quantified by HPLC. Nitrate levels in plasma of portal vein were assessed by chemiluminescence. Aqueous low-density lipoprotein (LDL) suspensions (200 microg protein/mL) were incubated with CuCl(2) (300 micromol/L) in the absence and presence of SNAC (300 micromol/L) for 15 h at 37 degree Celsius. Extent of LDL oxidation was assessed by fluorimetry. Linoleic acid (LA) (18.8 micromol/L) oxidation was induced by soybean lipoxygenase (SLO) (0.056 micromol/L) at 37 degree Celsius in the presence and absence of N-acetylcysteine (NAC) and SNAC (56 and 560 micromol/L) and monitored at 234 nm.
Animals in the control group developed moderate macro and microvesicular fatty changes in periportal area. SNAC-treated animals displayed only discrete histological alterations with absence of fatty changes and did not develop liver steatosis. The absence of NAFLD in the SNAC-treated group was positively correlated with a decrease in the concentration of LOOH in liver homogenate, compared to the control group (0.7+/-0.2 nmol/mg vs 3.2+/-0.4 nmol/mg protein, respectively, P<0.05), while serum levels of aminotransferases were unaltered. The ability of SNAC in preventing lipid peroxidation was confirmed in in vitro experiments using LA and LDL as model substrates.
Oral administration of SNAC prevents the onset of NAFLD in Wistar rats fed with choline-deficient diet. This effect is correlated with the ability of SNAC to block the propagation of lipid peroxidation in vitro and in vitro.
评估S-亚硝基-N-乙酰半胱氨酸(SNAC)抑制脂质过氧化的潜力以及口服SNAC对动物模型中非酒精性脂肪性肝病(NAFLD)的预防作用。
通过胆碱缺乏饮食诱导Wistar雄性大鼠发生NAFLD,持续4周。将接受SNAC治疗的动物(n = 6)(每天口服1.4 mg/kg SNAC)与2个对照组进行比较:一组(n = 6)接受PBS溶液,另一组(n = 6)接受NAC溶液(每天7 mg/kg)。对宏观和微观空泡脂肪变化、其区域分布、坏死灶、门静脉和小叶静脉周围纤维化以及具有区域分布的炎性浸润等组织学变量进行半定量分析。通过高效液相色谱法对肝脏匀浆样品中的脂质过氧化物(LOOHs)进行定量。通过化学发光法评估门静脉血浆中的硝酸盐水平。将水性低密度脂蛋白(LDL)悬浮液(200 μg蛋白/mL)在不存在和存在SNAC(300 μmol/L)的情况下与CuCl₂(300 μmol/L)在37℃孵育15小时。通过荧光法评估LDL氧化程度。在37℃下,在不存在和存在N-乙酰半胱氨酸(NAC)和SNAC(56和560 μmol/L)的情况下,用大豆脂氧合酶(SLO)(0.056 μmol/L)诱导亚油酸(LA)(18.8 μmol/L)氧化,并在234 nm处进行监测。
对照组动物在门静脉周围区域出现中度宏观和微观空泡脂肪变化。接受SNAC治疗的动物仅表现出离散的组织学改变,无脂肪变化,未发生肝脂肪变性。与对照组相比,SNAC治疗组中NAFLD的缺失与肝脏匀浆中LOOH浓度的降低呈正相关(分别为0.7±0.2 nmol/mg对3.2±0.4 nmol/mg蛋白,P<0.05),而血清氨基转移酶水平未改变。使用LA和LDL作为模型底物的体外实验证实了SNAC预防脂质过氧化的能力。
口服SNAC可预防胆碱缺乏饮食喂养的Wistar大鼠发生NAFLD。这种作用与SNAC在体内外阻断脂质过氧化传播的能力相关。